AQS — Aequus Pharmaceuticals Balance Sheet
0.000.00%
- CA$0.66m
- CA$7.23m
- CA$0.58m
Annual balance sheet for Aequus Pharmaceuticals, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1.72 | 2.44 | 0.295 | 0.215 | 0.05 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.78 | 0.941 | 0.31 | 0.032 | 0.058 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 2.77 | 3.59 | 0.903 | 0.436 | 0.282 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.366 | 0.242 | 0.789 | 0.651 | 0.518 |
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Total Assets | 3.13 | 4.35 | 1.69 | 1.09 | 0.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 0.384 | 2.46 | 2.38 | 4.8 | 6.8 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 2.56 | 2.56 | 3.07 | 5.38 | 7.26 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.574 | 1.79 | -1.38 | -4.29 | -6.45 |
Total Liabilities & Shareholders' Equity | 3.13 | 4.35 | 1.69 | 1.09 | 0.8 |
Total Common Shares Outstanding |